MHC class II and PLA2R investigating the epitope presentation deficits driving antibody production in membranous nephropathy.

Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, particularly affecting the glomerular region of the kidney. While MN can occur at any age, its onset typically peaks in individuals in their 50s. It is characterized by subepithelial immune complex deposits that thicken the glomerular basement, impairing filtration and causing proteinuria. While secondary MN is linked to conditions, such as hepatitis B, malignancies, autoimmune diseases, and drug exposure, primary MN (PMN) is often autoimmune in origin and is distinguished by the presence of autoantibodies against the M-type phospholipase A2 receptor (PLA2R) predominance of IgG4, which are absent in most secondary forms. The discovery of PLA2R antibodies has revolutionized PMN diagnosis and monitoring, offering a non-invasive biomarker that correlates with disease activity and remission. Diagnostic techniques, such as immunofluorescence and transmission electron microscopy, reveal characteristic IgG4 and C3 deposition, and podocyte damage. For better prognostic and diagnostic outcomes, reliance on PLA2R-IgG4 specific antibodies is needed, as this approach offers higher specificity and sensitivity compared to simply detecting the concentration of PLA2R-IgG antibodies. While there are better diagnostic and therapeutic options, challenges remain in fully elucidating the mechanisms behind antibody production and their role in disease progression. This review highlights the central mechanism that triggers PLA2R-associated immune responses by T cells, which examined these molecular interactions. Additionally, identifying novel PLA2R epitopes that bind to MHC II molecules, which is an important step moving from the current unspecific immunosuppressive therapies toward antigen-specific MN treatments.